S
Sumit Kumar
Researcher at Bristol-Myers Squibb
Publications - 6
Citations - 204
Sumit Kumar is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Granulation & Ultimate tensile strength. The author has an hindex of 3, co-authored 6 publications receiving 31 citations.
Papers
More filters
Journal ArticleDOI
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.
Sonal V Bhujbal,Biplob Mitra,Uday Jain,Yuchuan Gong,Anjali Agrawal,Shyam Karki,Lynne S. Taylor,Sumit Kumar,Qi Tony Zhou +8 more
TL;DR: This review provides an updated overview of manufacturing techniques for preparing ASDs, and selection strategies are proposed to identify suitable manufacturing methods, which may aid in the development of ASDs with satisfactory physical stability.
Journal ArticleDOI
3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment.
Atabak Ghanizadeh Tabriz,Uttom Nandi,Andrew P. Hurt,Ho-Wah Hui,Shyam Karki,Yuchuan Gong,Sumit Kumar,Dennis Douroumis +7 more
TL;DR: The work illustrated the potential application of FDM technology in the development of oral fixed dose combination for personalized clinical treatment by minimizing the degradation of RFC in the acidic condition and potentially avoid drug-drug interaction.
Journal ArticleDOI
Investigation on hot melt extrusion and prediction on 3D printability of pharmaceutical grade polymers
Atabak Ghanizadeh Tabriz,Nick Scoutaris,Yuchuan Gong,Ho-Wah Hui,Sumit Kumar,Dennis Douroumis +5 more
TL;DR: In this paper, a range of plain and drug loaded polymers were investigated and assessed for their printability in comparison to commercial filaments and principal component analysis was used to compare the printability of the polymer and to identify the contribution of each mechanical property.
Journal ArticleDOI
Role of wetting agents and disintegrants in development of danazol nanocrystalline tablets.
TL;DR: To evaluate the effect of wetting agents and disintegrants on the dissolution performance of dried nanocrystals of an active pharmaceutical ingredient (API) with poor wetting property, Danazol, a BCS Class II compound with high LogP and low polar surface area, was chosen as a model compound.
Journal ArticleDOI
A Novel Use of Nanocrystalline Suspensions to Develop Sub-Microgram Dose Micro-Tablets.
Saikishore Meruva,Prajwal Thool,Yuchuan Gong,Anjali Agrawal,Shyam Karki,William Bowen,Biplob Mitra,Sumit Kumar +7 more
TL;DR: In this article, a novel use of nanocrystalline suspension combined with high shear wet granulation for the first time was presented, which resulted in excellent content uniformity among individual micro-tablets even at a dose strength as low as 0.16 mcg, whereas micronized drug resulted in unacceptable CU even at 5x higher dose strength (0.8 mcg).